Ophthalmology

The systematic review and meta-analysis of 13 studies found no evidence to support the use of topical NSAIDs for the treatment of central serous chorioretinopathy.

The analysis of questionnaire responses in Sweden suggests the socioeconomic factor of low household income had a crucial impact on vision-related quality of life.

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

Outlook Therapeutics announced receipt of the CRL exactly one year after resubmission of their BLA for ONS-5010 as a treatment for wet age-related macular degeneration, which would have been the first indication for a retinal disease given to an ophthalmic version of bevacizumab.

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

Experts discuss prospective therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) treatment.

Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

A new analysis suggests pseudomyopia was an independent risk factor for myopia development among school-aged children in China.

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.